Innovative Therapeutic Focus Oblique Therapeutics specializes in developing antibody-based medicines for severe diseases with high unmet medical needs, particularly in pain management. This focus positions the company to benefit from partnerships with pharmaceutical firms seeking breakthrough treatments in these areas.
Strategic Collaborations Recent partnerships with AAX Biotech and Targovax demonstrate active collaboration efforts in advancing antibody technologies and delivery methods, providing potential avenues for joint development and licensing agreements.
Emerging Market Position Despite modest current revenue of under 1 million USD, Oblique’s recent funding of 2.5 million USD indicates investor confidence in its innovative pipeline, making it an attractive partner for co-developing novel therapies.
Technology and Platform Utilizing the proprietary Abiprot platform to identify accessible epitopes for antibody development offers potential for scalable collaborations with biotech and pharma companies interested in next-generation antibody technologies.
Targeted Disease Areas Focusing on pain and intracellular targets like TRPV1 allows for strategic marketing to pharma companies aiming to expand their portfolio in analgesics and complex disease treatments, opening up opportunities for licensing and co-commercialization.
$25M$50M
$10M$25M
$1M$10M
$1M$10M
$10M$25M
$1M$10M
$1M
$1M$10M
Oblique Therapeutics AB (publ.) uses 8 technology products and services including WordPress, RSS, Twemoji, and more. Explore Oblique Therapeutics AB (publ.)'s tech stack below.
| Oblique Therapeutics AB (publ.) Email Formats | Percentage |
| First.Last@obliquet.com | 73% |
| First@obliquet.com | 27% |
Pharmaceutical ManufacturingVästra Götaland, Sweden11-50 Employees
Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need with an internal pipeline focusing on pain. The company uses Abiprot®, a proprietary, next-generation antibody platform to identify accessible epitopes for antibody development.
Company Overview
Funding & FinancialsOblique Therapeutics AB (publ.) has raised a total of $2.5M of funding over 1 rounds. Their latest funding round was raised on Dec 11, 2015 in the amount of $2.5M.
Oblique Therapeutics AB (publ.)'s revenue is estimated to be in the range of $1M
Funding & FinancialsOblique Therapeutics AB (publ.) has raised a total of $2.5M of funding over 1 rounds. Their latest funding round was raised on Dec 11, 2015 in the amount of $2.5M.
Oblique Therapeutics AB (publ.)'s revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com